SUNG, YOUNG CHUL,성영철,KIM, SAE WON,김세원,KANG, MOON CHEOL,강문철,SUNG, YOUNG CHULKR,KIM, SAE WONKR,KANG, MOON CHEOLKR
申请号：
KR1020170122238
公开号：
KR1020180033095A
申请日:
2017.09.22
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to a novel natural killer cell line and a use thereof, and more specifically, to a novel natural killer cell line in which CD2, CD11a, CD25, CD45, CD54, CD56 and HLA-DR are positive； and CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ and TCRγδ are negative. The present invention also relates to a pharmaceutical composition for treating cancer including the natural killer cell line, and uses thereof.본 발명은 신규 자연살해 세포주 및 그의 용도에 관한 것으로서, 보다 구체적으로는 CD2, CD11a, CD25, CD45, CD54, CD56 및 HLA-DR은 양성； 및 CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ 및 TCRγδ는 음성인 신규 자연살해 세포주 및 이를 포함하는 암 치료용 약학적 조성물 등 그의 용도를 제공한다.
